1. Can you predict the top neuroscience antibody targets?

    We’re just a few weeks out from the Society for Neuroscience’s annual event, so with this field at the front of our minds we’ve delved into CiteAb’s data to offer you a neuroscience special this week. Today we’re looking at data for the main antibody protein targets for neuroscience research – before reading ahead why […]

  2. GBSI-hosted antibody validation event outlines new approaches

    Last week, our founder Dr Andrew Chalmers attended the Antibody Validation: Standards, Policies, and Practices workshop in California. The event aimed to develop validation approaches to increase reproducibility in preclinical research and improve the chances for breakthroughs in treatments and cures. More than 100 scientists and researchers spent three days working through the complexities uniquely […]

  3. New collaborations harness CiteAb data

    Over the past month we’ve embarked on two new partnerships that will see CiteAb data help more researchers around the world to do their work. We are now working with USA-based FluoroFinder and UK-based Chromocyte, both companies that aim to help scientists design complex flow cytometry experiments. FluoroFinder was set up in 2014 by Roland […]

  4. Who is winning the market share race?

    In the data we’re releasing today we take a look at which suppliers are gaining the most market share in the primary and secondary research antibody markets, and what their competitors can do to keep up.   As this is the first time CiteAb data has shed light on the companies leading in the secondary […]

  5. Catch up on AbVal16!

    If you follow our blog regularly you couldn’t have missed that last week our team was busy hosting antibody suppliers, academic and industry researchers and professionals from the pharmaceutical and biotech sector here in Bath for the 2nd International Antibody Validation Event. If you weren’t able to join us last week, here is a quick […]

Search our blog